PERSPECTA

News from every angle

← Back to headlines

Zevra Outlines CHMP Reexamination Timing for MIPLYFFA

Zevra Therapeutics has outlined the timing for the CHMP reexamination of MIPLYFFA, with an opinion expected in Q4, and the Orange Book listing for the drug extended to 2041.

6 Aug, 02:32 — 6 Aug, 02:32
PostShare

Sources

Showing 1 of 1 sources
seeking-alphaMixed19d ago

Zevra outlines CHMP reexamination timing with Q4 opinion expected, as MIPLYFFA Orange Book listing extends to 2041

Read full article →

Related Stories

OnlyFans Owner Received Over $700 Million Payout Before Death

20m ago

China Warns of Retaliation Against U.S. Over Iran Sanctions

25m ago

Japan's Corporate Services Inflation Accelerates in July

41m ago

Multiple Company Executives Sell Shares in Various Transactions

1h ago